Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471367 · ClinicalTrials.gov registry record · Phase 1
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00471367 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 44 participants.
The verdict
NCT00471367, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study has two parts (A and B). The primary purpose of Part A is to find the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a twice a week basis. For Part B, an additional 20 patients will be treated at the maximum dose identified in Part A. AZD4877 is an Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth
Interventions
- DRUG AZD4877
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00471367
The ClinicalTrials.gov registry entry for NCT00471367 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD4877 is the first listed.
NCT00471367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00471367 about?
NCT00471367 is a clinical study titled "Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877". This study has two parts (A and B). The primary purpose of Part A is to find the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a twice a week basis. For Part B, an additional 20 patients will be treated at ...
What is the current status of trial NCT00471367?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2007-04. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00471367?
The interventions under investigation include: AZD4877 (DRUG).
Who is sponsoring clinical trial NCT00471367?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.